Oppenheimer Asset Management Inc. Purchases 14,165 Shares of Genmab A/S (NASDAQ:GMAB)

Oppenheimer Asset Management Inc. raised its position in shares of Genmab A/S (NASDAQ:GMAB) by 6.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 232,243 shares of the company’s stock after purchasing an additional 14,165 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Genmab A/S were worth $5,662,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GMAB. DDD Partners LLC bought a new stake in Genmab A/S in the 2nd quarter worth approximately $8,860,000. Capital International Investors lifted its holdings in shares of Genmab A/S by 7.8% in the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after acquiring an additional 315,355 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after acquiring an additional 145,689 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after purchasing an additional 103,859 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Genmab A/S during the 2nd quarter valued at $1,354,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Down 2.2 %

Shares of GMAB stock opened at $21.18 on Friday. The firm has a market capitalization of $14.02 billion, a price-to-earnings ratio of 20.56, a PEG ratio of 0.70 and a beta of 0.99. The stock has a fifty day moving average of $24.08 and a 200 day moving average of $26.28. Genmab A/S has a 52 week low of $21.17 and a 52 week high of $32.89.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the company posted $0.47 earnings per share. Equities research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on GMAB shares. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.